The Medicines and Healthcare products Regulatory Agency (MHRA) has approved an adapted version of the Nuvaxovid COVID-19 vaccine that targets the ...

The MHRA has approved Novavax’s updated Nuvaxovid vaccine for the latest subvariant in individuals aged 12 and older. This ...

Novavax (NVAX) stock falls 12% in premarket as company cuts full-year revenue guidance due to a lower sales outlook for its ...

Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...

BofA lowered the firm’s price target on Novavax (NVAX) to $12 from $14 and keeps a Neutral rating on the shares. The company announced ...

Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...

Novavax has inked another settlement for a past COVID-19 vaccine supply deal. | Novavax has inked another settlement for a ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

On November 1, Novavax, Inc. (NASDAQ:NVAX) and the U.K. Health Security Agency, representing the U.K. Secretary of State for ...

The government’s deal with Maryland-based Novavax requires the company to obtain regulatory approval for a vaccine using ingredients made at the Biologics Manufacturing Centre (BMC) in Montreal before ...

The CHMP also recommended a revised composition for Nuvaxovid, an already approved vaccine that targets the JN.1 variant of the SARS-CoV-2 virus. The news follows recommendations by the European ...